/

Empresas

Re

No verificado

RevBio, Inc.

Sobre qué escribimos

BiotecnologíaHigiene alimentariaIndustriaMedicina alternativaMultimedia

7 Comunicados de prensa

Ver todos los comunicados de prensa

04/11/2025

RevBio® Receives First FDA Approval for a "Bone Glue" to Treat Extremity Fractures in a Clinical Trial

Fuente

Editor

1.00

0

06/10/2025

RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures

Fuente

Editor

1.00

0

29/05/2025

RevBio Expands Globally into the United Kingdom with its Second Cranial Flap Fixation Clinical Trial for its Regenerative Bone Adhesive

Fuente

Editor

1.00

0

17/03/2025

Multimedia

Industria

Ciencia

Material médico sanitario

Medicina - Varios

Higiene alimentaria

Odontología

Biotecnología

Medicina alternativa

Salud

RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product

Fuente

Editor

1.00

0

30/01/2025

RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office

Fuente

Editor

1.00

0

11/12/2024

Multimedia

Industria

Sanidad

Ciencia

Material médico sanitario

Medicina - Varios

Biotecnología

Medicina alternativa

Higiene alimentaria

Salud

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation

Fuente

Editor

1.00

0

16/09/2024

RevBio Receives a $2.4 Million NIH Grant to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation and Enrolls First Five Patients

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0